Source comparison
PT-141 Dosage HSDD 2026: Clinical Evidence Comparison
1.5mg 42% (FSFI +0.8 points) 18% 6% Subtherapeutic for most patients. Used only in MC4R hypersensitive cases or extreme nausea history Rarely optimal. Most patients underperform at this dose 1.75mg (FDA standard) 60% (FSFI +1.3 points) 32% 12% First-line start
This comparison does not assign a generated winner or score.
- 1.5mg
- 42% (FSFI +0.8 points)
- 18%
- 6%
- Subtherapeutic for most patients. Used only in MC4R hypersensitive cases or extreme nausea history
- Rarely optimal. Most patients underperform at this dose
- 1.75mg (FDA standard)
- 60% (FSFI +1.3 points)
- 32%
- 12%
- First-line starting dose for all HSDD patients. Allows assessment of individual response before escalation
- Correct starting point. Titrate from here based on 4-dose response
- 2.0mg
- 68% (FSFI +1.6 points)
- 41%
- 16%
- Escalation dose for partial responders at 1.75mg who tolerate initial dosing well
- Sweet spot for many partial responders. Balance efficacy and tolerability
- 2.5mg
- 74% (FSFI +1.9 points)
- 54%
- 22%
- Maximum therapeutic dose. Reserved for non-responders at 2.0mg with high nausea tolerance
- Highest efficacy but side effect burden limits real-world use
- 3.0mg+
- 76% (FSFI +2.0 points)
- 68%
- 31%
- Exceeds FDA-approved range. Discontinuation rate above 40% negates marginal efficacy gain
- Not clinically recommended. Adverse event profile outweighs benefit
- FSFI improvement data from Phase III RECONNECT trials (2017–2019). Response rate defined as ≥1.2-point increase in FSFI desire domain score after 8 weeks of treatment.